Immunitybio

Immunitybio Equity Growth

The Year-over-Year Equity Growth of Immunitybio (IBRX) as of Oct 20, 2026 is -2.14 %. In the previous year, Year-over-Year Equity Growth was 16.68 % — a change of -112.84% (lower).

Equity Growth

-2.14 %

YoY

-112.84%

Last updated:

Year-over-Year Equity Growth of Immunitybio is 2025 -2.14 % . Year-over-Year Equity Growth of Immunitybio was 2024 16.68 % . It decreases by -112.84% lower compared to the previous year.

The Immunitybio Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
-33.28 USD
Jan 1, 2019
-17.35 USD
Jan 1, 2020
-199.28 USD
Jan 1, 2021
-102.13 USD
Jan 1, 2022
-84.71 USD
Jan 1, 2023
-31.22 USD
Jan 1, 2024
16.68 USD
Jan 1, 2025
-2.14 USD
The Immunitybio Equity Growth history
YEAREquity GrowthYoY
-2.14 %-112.84%
16.68 %-153.41%
-31.22 %-63.15%
-84.71 %-17.06%
-102.13 %-48.75%
-199.28 %+1,048.81%
-17.35 %-47.88%
-33.28 %+30.96%
-25.42 %+44.59%
-17.58 %-103.45%
509.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

Year-over-Year Equity Growth of Immunitybio is -2.14 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Immunitybio since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Immunitybio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Immunitybio

All Key Metrics — Immunitybio